U.K. Deal Reached For 5-Year Price Cap On State’s Branded Drug Regulation
This article was originally published in The Pink Sheet Daily
Executive Summary
The first-ever cap on U.K. National Health Service drug price increases will last five years. Pharma firms reluctantly agreed to the restrictions, but say they are excessive and further undermine Britain’s attractiveness as a place to conduct drug R&D.